BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,800 | -96.0% | 20,000 | -94.6% | 0.01% | -96.3% |
| Q4 2022 | $4,216,604 | -24.3% | 367,300 | -16.9% | 0.37% | -31.5% |
| Q3 2022 | $5,568,000 | +19.1% | 441,900 | 0.0% | 0.55% | +28.5% |
| Q2 2022 | $4,675,000 | -35.2% | 441,900 | -0.3% | 0.42% | -24.4% |
| Q1 2022 | $7,210,000 | +15.7% | 443,400 | -1.4% | 0.56% | +28.9% |
| Q4 2021 | $6,230,000 | -2.1% | 449,800 | +1.6% | 0.44% | -15.7% |
| Q3 2021 | $6,364,000 | -7.8% | 442,900 | +1.4% | 0.52% | -5.7% |
| Q2 2021 | $6,904,000 | +55.8% | 436,690 | +0.2% | 0.55% | +31.1% |
| Q1 2021 | $4,432,000 | +98.2% | 435,790 | +45.2% | 0.42% | +79.4% |
| Q4 2020 | $2,236,000 | +272.0% | 300,190 | +71.5% | 0.23% | +228.2% |
| Q3 2020 | $601,000 | +214.7% | 175,000 | +337.5% | 0.07% | +184.0% |
| Q2 2020 | $191,000 | – | 40,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |